A 28-year-old woman with a history of recurrent muscle pain and dark urine after prolonged exercise is investigated. Serum carnitine is low, and muscle biopsy shows lipid accumulation. Which finding best distinguishes primary carnitine deficiency from carnitine palmitoyltransferase (CPT) I deficiency?

Explanation

## Distinguishing Primary Carnitine Deficiency from CPT I Deficiency ### Overview of the Carnitine Shuttle System Carnitine is essential for transporting long-chain fatty acids (>12 carbons) across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. Defects at different steps produce distinct biochemical and clinical patterns. ### Pathophysiology Comparison | Feature | Primary Carnitine Deficiency | CPT I Deficiency | |---------|------------------------------|------------------| | **Defect** | Carnitine transporter (SLC22A5) mutation | CPT I enzyme deficiency | | **Plasma carnitine** | **Low** (↓ uptake/transport) | **Normal or elevated** (carnitine accumulates) | | **Tissue carnitine** | **Low** (cannot enter cells) | **Normal** (can enter, but not used) | | **Mitochondrial β-oxidation** | Impaired (insufficient carnitine) | Impaired (cannot form acyl-carnitine) | | **Acylcarnitines** | Low (substrate unavailable) | **Elevated long-chain acylcarnitines** (substrate accumulates) | | **Primary presentation** | Cardiomyopathy, hepatic encephalopathy, hypoglycemia | Muscle pain, myoglobinuria, exercise intolerance | | **Organ involvement** | Multi-organ (heart, liver, brain) | Primarily skeletal muscle | ### Key Discriminating Feature **High-Yield:** The **plasma and tissue carnitine level** is the primary discriminator: - **Primary carnitine deficiency** → **LOW plasma carnitine** (transport defect prevents uptake) - **CPT I deficiency** → **NORMAL or HIGH plasma carnitine** (carnitine accumulates because it cannot be utilized) **Key Point:** In CPT I deficiency, carnitine is present but functionally unavailable for β-oxidation because the enzyme cannot conjugate it to long-chain acyl-CoA. ### Secondary Biochemical Findings **Clinical Pearl:** Tandem mass spectrometry distinguishes these further: - **Primary carnitine deficiency**: Low free carnitine, low acylcarnitines (substrate limitation) - **CPT I deficiency**: Normal/high free carnitine, **elevated long-chain acylcarnitines** (substrate accumulation) ### Treatment Implications - **Primary carnitine deficiency** → Responds to **L-carnitine supplementation** (replaces deficient cofactor) - **CPT I deficiency** → Does NOT respond to carnitine (enzyme defect cannot be bypassed); managed with **low-fat, high-carbohydrate diet** and avoidance of prolonged fasting ### Clinical Context A patient with **low plasma carnitine + hepatic encephalopathy + cardiomyopathy** → Primary carnitine deficiency (multi-organ involvement, systemic carnitine depletion). A patient with **normal carnitine + exercise-induced myoglobinuria + muscle lipid storage** → CPT I deficiency (muscle-specific, carnitine present but non-functional).